Literature DB >> 3864428

Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser.

J O Miners, L M Wing, D J Birkett.   

Abstract

The metabolism of debrisoquine and theophylline has been studied in a healthy male who was identified as a slow hydroxylator of tolbutamide. Tolbutamide clearance in this subject was three-fold lower than the lowest tolbutamide clearance observed in other healthy males and the drug's half-life was approximately three-fold longer. Despite this, his ability to 4-hydroxylate debrisoquine and both N-demethylate and 8-hydroxylate theophylline was normal. Along with previously published information the data from this subject suggest that tolbutamide hydroxylation, debrisoquine hydroxylation, theophylline N-demethylation, and theophylline 8-hydroxylation involve four distinct isozymes of cytochrome P-450. Furthermore, this report illustrates the difficulties of using the metabolic clearance of a model drug to predict the ability of an individual to clear a range of metabolised drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3864428     DOI: 10.1111/j.1445-5994.1985.tb04052.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  8 in total

Review 1.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  A screening test for slow metabolisers of tolbutamide.

Authors:  M A Page; J S Boutagy; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

3.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

Authors:  C J Doecke; M E Veronese; S M Pond; J O Miners; D J Birkett; L N Sansom; M E McManus
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

5.  Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.

Authors:  G F Peart; J Boutagy; G M Shenfield
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Co-regulation of phenytoin and tolbutamide metabolism in humans.

Authors:  W Tassaneeyakul; M E Veronese; D J Birkett; C J Doecke; M E McManus; L N Sansom; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

Review 7.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

Review 8.  PharmVar GeneFocus: CYP2C9.

Authors:  Katrin Sangkuhl; Karla Claudio-Campos; Larisa H Cavallari; Jose A G Agundez; Michelle Whirl-Carrillo; Jorge Duconge; Andria L Del Tredici; Mia Wadelius; Mariana Rodrigues Botton; Erica L Woodahl; Stuart A Scott; Teri E Klein; Victoria M Pratt; Ann K Daly; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-07-12       Impact factor: 6.903

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.